Olmutinib

Overview

Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | BTK

Product Information

• Catalog No.: B0084-470842
• CAS No.: 1353550-13-6
• Molecular Formula: C26H26N6O2S
• Molecular Weight: 486.18
• Purity: >98%
• Solubility: DMSO 97 mg/mL (199.34 mM)

Source

Original product source